At SK Life Science Labs, we believe targeted protein degradation (TPD) will change the future of oncology and immunology. Together, our leadership team has more than 120 years of R&D experience in drug discovery and development.
SK Life Science Labs is a subsidiary of SK Biopharmaceuticals, a company focused on developing innovative, next-generation drugs. Both are part of SK Group, a global conglomerate with headquarters in Korea, a leader in energy, chemical, semiconductor, and telecommunications industries, and one of TIME’s 100 Most Influential Companies of 2023.
